The expression of CD90 is increased in a grade-dependent manner, which is similar to CD44; CD90 is capable of distinguishing grade III/IV gliomas from grade I/II gliomas and normal brain tissue because CD90 mainly expresses in high-grade gliomas and rarely expresses in low-grade gliomas and normal brain tissue (57). Here, THY1 is linked to central nervous system cancer.